The increasing genomic complexity of acute myeloid leukemia

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 3-4, 2014, Pages 209-213

  Rowe, Jacob M ^a,b,c,d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c NORTHWESTERN UNIVERSITY   (United States)

^d SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Acute Leukemia Forum acute myeloid leukemia; AML genetics epigenetics mutations

Indexed keywords

DNA;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PATIENT; CANCER PROGNOSIS; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENOMIC COMPLEXITY; HUMAN; PARAMETERS; PRIORITY JOURNAL; REVIEW; ACUTE MYELOBLASTIC LEUKEMIA; CHROMOSOME 16; CHROMOSOME INVERSION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY;

CHROMOSOME INVERSION; CHROMOSOMES, HUMAN, PAIR 16; DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 84923227031     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.10.001     Document Type: Review

References (12)

1. Cancer Genome Atlas Research Network Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia N Engl J Med 368 2013 2059 2074
2. P. Paschka, J. Du, and R.F. Schlenk Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16; 16): a study of the German-Austrian AML Study Group (AMLSG) Blood 121 2013 170 177
3. G. Marcucci, P. Yan, and K. Maharry Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score J Clin Oncol 32 2014 548 556
4. J.O. Moore, S.L. George, and R.K. Dodge Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222 Blood 105 2005 3420 3427
5. T. Buchner, W.E. Berdel, and C. Haferlach Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group J Clin Oncol 27 2009 61 69
6. H.F. Fernandez, Z. Sun, and X. Yao Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 2009 1249 1259
7. A.K. Burnett, R.K. Hills, and D. Milligan Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol 29 2011 369 377
8. S.H. Petersdorf, K.J. Kopecky, and M. Slovak A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia Blood 121 2013 4854 4860
9. S.N. Dinner, F.J. Giles, and J.K. Altman New strategies for relapsed acute myeloid leukemia: fertile ground for translational research Curr Opin Hematol 21 2014 79 86
10. L.I. Shlush, S. Zandi, and A. Mitchell Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia Nature 506 2014 328 333
11. J.R. Prensner, and A.M. Chinnaiyan Metabolism unhinged: IDH mutations in cancer Nat Med 17 2011 291 293
12. E. Stein, M. Tallman, and D.A. Pollyea Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies [abstract] Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR 2014 CT103 [abstr]